###begin article-title 0
###xml 46 50 46 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 58 62 58 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
Levels of vascular endothelial growth factor-A165b (VEGF-A165b) are elevated in experimental glaucoma
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 311 314 311 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 359 363 359 363 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
Although ischemia has previously been suggested to contribute to the pathogenesis of glaucoma, neovascularization is not implicated in glaucoma. Because vascular endothelial growth factor-A (VEGF-A) is a key mediator in neovascularization response, we investigated the levels of the major pro-angiogenic (VEGF-A164) and anti-angiogenic VEGF-A subtypes (VEGF-A165b) in the retina during experimental glaucoma.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 417 420 417 420 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 431 435 431 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 818 821 818 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 832 836 832 836 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 37 41 <span type="species:ncbi:10116">rats</span>
###xml 239 243 <span type="species:ncbi:10116">rats</span>
###xml 521 525 <span type="species:ncbi:10116">rats</span>
Glaucoma was induced unilaterally in rats by injecting 1.9 M hypertonic saline solution in the episcleral veins. The contralateral eye served as the control. The intraocular pressure (IOP) of each eye was measured via Tonopen in conscious rats. Eyes were enucleated either on the 5th or the 10th day of elevated IOP. Whole retinal lysates were separated by SDS-PAGE and transferred to PVDF membranes. Levels of VEGF-A164 and VEGF-A165b were analyzed by western blotting using specific antibodies. In a different group of rats, retinal ganglion cells were retrogradely labeled by injecting Fluorogold in the superior colliculus a week before the induction of glaucoma. After the eyes were enucleated on the fifth day of elevated IOP, posterior eye cups were sectioned using a cryostat. Levels and localization of VEGF-A164 and VEGF-A165b were examined in retinal sections by immunohistochemistry.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 6 9 6 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 272 276 272 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 339 343 339 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 505 509 503 507 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 651 654 649 652 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 665 669 663 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 237 240 <span type="species:ncbi:10116">rat</span>
###xml 321 324 <span type="species:ncbi:10116">rat</span>
VEGF-A164 levels remained unchanged between the control and glaucomatous retinas after five days (p=0.341) and 10 days of elevated IOP (p=0.117). The presence of the anti-angiogenic VEGF-A isoform has not been previously reported in the rat. An antibody specific to VEGF-A165b detected the anti-angiogenic protein in the rat retina. VEGF-A165b levels were significantly increased (2.33+/-0.44 fold, p=0.014) in the glaucomatous retinas compared to those in controls after five days of elevated IOP. VEGF-A165b levels were not different (p=0.864) between the control and glaucomatous retinas following 10 days of elevated IOP. Expression of both VEGF-A164 and VEGF-A165b were observed in the retinal ganglion cells (RGC) and inner nuclear layer (INL).
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 76 80 76 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 124 127 124 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 169 173 169 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 241 244 241 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 322 326 322 326 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 371 374 371 374 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
Five day elevation of IOP leads to an increase in the anti-angiogenic VEGF-A165b levels but not in the pro-angiogenic VEGF-A164 levels in the glaucomatous retina. VEGF-A165b levels return to baseline after 10 days of elevated IOP, and VEGF-A164 levels remain unchanged. We speculate that the short-term elevation of VEGF-A165b levels and/or the unchanged levels of VEGF-A164 contribute to the lack of neovascularization in the glaucomatous retina.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 821 822 821 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 418 426 <span type="species:ncbi:9606">patients</span>
Glaucoma is a neurodegenerative disease of retinal ganglion cells (RGC) that leads to blindness. Although the most prominent risk factor for RGC death in glaucoma is elevated intraocular pressure (IOP), the sequence of events by which IOP causes RGC death still remains largely unknown. One possible mechanism is that elevated IOP can induce abnormalities in blood flow in the glaucomatous eye. In open-angle glaucoma patients, abnormal vascular autoregulation has been observed in the inferior temporal retinal artery, the central retinal artery, the circulation of the optic nerve head, the choroid, and the perifoveal macular capillaries [1-8]. It has been suggested that dysregulation of blood flow may lead to decreased vascular perfusion in the retina and in the optic nerve head, resulting in an hypoxic response [9,10].
###end p 11
###begin p 12
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 370 373 370 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 561 565 561 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 586 591 <span type="species:ncbi:9606">human</span>
###xml 675 680 <span type="species:ncbi:10090">mouse</span>
In the classical view of hypoxia, the ischemic tissue compensates for a decrease in oxygen levels by forming new blood vessels, a process known as neovascularization [11]. VEGF-A is a key mediator in neovascularization in ischemic retinopathies [12-14]. There are several VEGF-A isoforms expressed from a single gene via alternative splicing [15,16]. Among these, VEGF-A165 is the most abundantly expressed pro-angiogenic isoform in the retina [17]. More recently, anti-angiogenic sister isoforms of VEGF-A have also been identified [18-20]. For example, VEGF-A165b, an anti-angiogenic human VEGF-A isoform, has been shown to inhibit VEGF-A induced neovascularization in the mouse retina following ischemia [21].
###end p 12
###begin p 13
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
There are only a few studies that have examined VEGF-A in glaucoma. VEGF levels were shown to be increased in the plasma of glaucoma patients when compared to that of healthy controls [22] and in the aqueous humor of glaucoma patients when compared to their plasma VEGF levels [23]. Despite these findings, neovascularization is not implicated in glaucoma, and the role of VEGF-A has not been examined in the glaucomatous retina.
###end p 13
###begin p 14
###xml 189 192 189 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 219 222 219 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 250 254 250 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 281 285 281 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 500 504 500 504 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 519 522 519 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 198 201 <span type="species:ncbi:10116">rat</span>
###xml 260 263 <span type="species:ncbi:10116">rat</span>
If ischemia contributes to the pathogenesis of glaucoma, why is there no neovascularization in glaucoma? To answer this apparent paradox, we investigated the levels of pro-angiogenic VEGF-A164 (the rat version of VEGF-A165) and anti-angiogenic VEGF-A165b (the rat version of VEGF-A165b) in normal and glaucomatous retinas after a short-term (five day) and an intermediate-term (10 day) elevation of IOP. Because of the lack of neovascularization in glaucoma, we hypothesized that the levels of VEGF-A165b but not VEGF-A164 would be increased in the glaucomatous retina.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Subjects
###end title 16
###begin p 17
###xml 5 9 <span type="species:ncbi:10116">rats</span>
###xml 83 87 <span type="species:ncbi:10116">Rats</span>
Male rats (retired breeder Brown Norway; 300-450 g; n=16) were used for the study. Rats had ad libitum access to food and water during the study and were kept on a 12 h illumination cycle. All animal related procedures were performed in accordance with the statement for the use of animals in research released by the Association for Research in Vision and Ophthalmology.
###end p 17
###begin title 18
Retrograde labeling of retinal ganglion cells
###end title 18
###begin p 19
###xml 0 4 <span type="species:ncbi:10116">Rats</span>
###xml 228 231 <span type="species:ncbi:10116">rat</span>
###xml 822 826 <span type="species:ncbi:10116">Rats</span>
Rats (n=4) were anesthetized with an intraperitoneal injection of 1.5 mg/kg of acepromazine maleate, 7.5 mg/kg of xylazine, and 75 mg/kg of ketamine (Webster Veterinary Supply, Sterling, MA). Following shaving of the head, each rat was placed in a stereotaxic instrument. The skin covering the skull was incised along the midline using a surgical blade, and the skull was exposed and leveled. Next, for each hemisphere, a 30-gauge stainless steel needle was lowered into the superior colliculus at 5.3 mm posterior to the bregma, 1.5 mm lateral to the midline, and 4.8 mm ventral to the skull surface. Using a 5 mul syringe (Hamilton, Reno, NV), 2 mul of Fluorogold solution (3% in PBS with 10% DMSO; Fluorochrome, Denver, CO) was injected over 10 min into each hemisphere. Following the injections, the skin was sutured. Rats were allowed to recover for a week before glaucoma was induced experimentally.
###end p 19
###begin title 20
Experimental induction of glaucoma
###end title 20
###begin p 21
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 176 179 <span type="species:ncbi:10116">rat</span>
###xml 314 318 <span type="species:ncbi:10116">Rats</span>
To elevate IOP, hypertonic saline solution (1.9 M) was unilaterally injected in the episcleral veins as described by Morrison and colleagues [24]. The contralateral eye of the rat served as the control. A maximum number of three injections that were two weeks apart were performed in the absence of IOP elevation. Rats that did not have an elevation of IOP after the third surgery were excluded from the study.
###end p 21
###begin title 22
Intraocular pressure measurements
###end title 22
###begin p 23
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 102 106 <span type="species:ncbi:10116">rats</span>
###xml 258 261 <span type="species:ncbi:10116">rat</span>
IOPs were measured with a TonoPen XL tonometer (Medtronic Ophthalmics, Jacksonville, FL) in conscious rats [25]. Measurements were taken between 10 AM and 2 PM. Before the first hypertonic saline injection, baseline IOPs for both eyes were measured for each rat. Following glaucoma inducing surgery, IOPs were measured three times a week. On each measurement day, an average of 15 readings was calculated for each eye. This study investigated a five day (n=6) and a 10 day elevation of IOP (n=6).
###end p 23
###begin title 24
Tissue preparation
###end title 24
###begin p 25
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 372 373 371 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 673 674 666 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 0 4 <span type="species:ncbi:10116">Rats</span>
Rats were sacrificed by CO2 inhalation either after five days or 10 days of elevated IOP. For western blotting, retinas were isolated from eyes obtained after five days and 10 days of elevated IOP (six pairs each). Retinas were placed in 200 mul of 1 mM of EDTA/EGTA/DTT, 10 mM of Hepes (pH=7.6), 0.5% Igepal (Sigma Chemical Co., St. Louis, MO), 42 mM of KCl, 5 mM of MgCl2, 1 mM of PMSF, and a tablet of protease inhibitors (Complete Mini, Roche Diagnostics, Mannheim, Germany). After retinas were sonicated and incubated for 15 min on ice, samples were spun at 21,000 rpm at 4 degreesC for 30 min. Retinal proteins were quantified by spectrophotometry using the Bio-Rad Dc Protein Assay (Bio-Rad Laboratories, Hercules, CA).
###end p 25
###begin p 26
For immunohistochemistry, four pairs of eyes that were enucleated after five days of elevated IOP were fixed with 4% paraformaldehyde for 20 min at room temperature. These eyes were previously back-labeled with Fluorogold. Next, the posterior eye cups were isolated and fixed with 4% paraformaldehyde for an additional 40 min at room temperature. After posterior eye cups were cryoprotected overnight in graded sucrose dilutions, they were placed in the optimal cutting temperature compound (Tissue-tek, Miles Diagnostic Division, Elkhart, IN) and were sectioned 16 mum thick using a cryostat.
###end p 26
###begin title 27
Western blotting
###end title 27
###begin p 28
###xml 174 177 174 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 164 167 <span type="species:ncbi:10116">rat</span>
###xml 726 732 <span type="species:ncbi:9986">rabbit</span>
###xml 804 809 <span type="species:ncbi:10090">mouse</span>
###xml 872 877 <span type="species:ncbi:10090">mouse</span>
###xml 1061 1065 <span type="species:ncbi:9925">Goat</span>
###xml 1071 1077 <span type="species:ncbi:9986">rabbit</span>
###xml 1146 1150 <span type="species:ncbi:9925">goat</span>
###xml 1156 1161 <span type="species:ncbi:10090">mouse</span>
###xml 1315 1318 <span type="species:ncbi:10116">rat</span>
Retinal proteins isolated after either five days or 10 days of elevated IOP were separated on Tris-HCl Ready-Gels (Bio-Rad Laboratories, Hercules, CA). Recombinant rat VEGF-A164 protein (25-250 ng; R&D Systems, Minneapolis, MN) was also loaded as a positive control in certain experiments. Proteins separated by SDS-PAGE were then transferred to polyvinylidene difluoride membranes (Immobilon-P; Millipore, Billerica, MA) for 1 h. After the membrane was blocked for 1 h at room temperature with 2% ECL Advance Blocking Agent (GE Healthcare, Piscataway, NJ) in Tris-buffered saline with Tween (TBS-T), it was incubated at 4 degreesC overnight with a primary antibody. The primary antibodies used in this study were as follows: rabbit polyclonal anti-VEGF (1:50; Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal anti-VEGF165B (1:1,000; Abcam, Cambridge, MA), and mouse monoclonal anti-alpha-tubulin (1:100,000; Sigma, Saint Louis, MO). The next day, membranes were incubated for 1 h at room temperature with peroxidase-conjugated secondary antibodies. Goat anti-rabbit IgG (1:10,000-1:40,000; Jackson ImmunoResearch, West Grove, PA) and goat anti-mouse IgG (1:20,000-1:100,000; Jackson ImmunoResearch) were the secondary antibodies used in the study. Both of these antibodies had minimal cross-reaction to rat serum proteins. Next, membranes were processed with ECL Advance Western Blotting Detection Kit (GE Healthcare, Piscataway, NJ) and exposed to Kodak BioMax Light Film (Crestream Health, Inc., Rochester, NY).
###end p 28
###begin title 29
Densitometry and statistical analysis
###end title 29
###begin p 30
###xml 660 661 656 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
A Personal Densitometer SI (Molecular Dynamics, Sunnyvale, CA) was used to scan the exposed films. The density of the protein of interest on the film was measured using ImageQuant 1.2 (Molecular Dynamics). First, the background density was subtracted from the density of each band. Next, the densitometric reading of the protein of interest was normalized to alpha-tubulin readings, which served as loading controls. For each retina pair, the normalized densitometric reading from the glaucomatous retina was divided by the reading from the control retina. Then, the ratios from different pairs of retinas were averaged. For statistical analysis, a one-sample t-test was used to evaluate the significance of the ratios for a given protein (one-tailed, hypothesized mean=1, alpha level=0.05). Data were reported as mean+/-standard error of the mean (SEM) in the text.
###end p 30
###begin title 31
Immunohistochemistry
###end title 31
###begin p 32
###xml 95 99 <span type="species:ncbi:9925">goat</span>
###xml 401 406 <span type="species:ncbi:10090">mouse</span>
###xml 451 456 <span type="species:ncbi:10090">mouse</span>
###xml 577 581 <span type="species:ncbi:9925">goat</span>
###xml 587 592 <span type="species:ncbi:10090">mouse</span>
Retinal sections from four pairs of eyes were blocked for 1 h at room temperature in 4% normal goat serum and 0.3% Triton-X 100 in 1X PBS, pH 7.4. Sections were incubated with the primary antibody overnight at 4 degreesC. Some sections were incubated in blocking solution without the primary antibody and were used as negative controls. The primary antibodies and the dilutions used in the study were mouse monoclonal anti-VEGF (20 mug/ml; Sigma) and mouse monoclonal anti-VEGF165B (1:500; Abcam). The following day, sections were incubated with the Alexa Fluor 594-conjugated goat anti-mouse secondary antibody (1:500; Invitrogen, Carlsbad, CA) for 1 h at room temperature. After the sections were treated with Prolong Gold anti-fade reagent, staining was visualized using an Olympus BX51 microscope (Olympus, Center Valley, PA).
###end p 32
###begin p 33
On our BX51 microscope, we used UPlanApo 0.70 NA 20X (Olympus) and UPlanApo 0.85 NA 40X (Olympus) objective lenses through a 10X ocular or camera lens to image our retinal sections for a total magnification of 200X or 400X, respectively. Excitation/emission filter cubes used for a given fluorophore were 11006v2 Gold (Chroma, Rockingham, VT) for Fluorogold and N41004 HQ Texas Red (Chroma) for Alexa Fluor 594. We used DPController 1.2.1.108 (Olympus) in conjunction with the DP70 color camera (Olympus) affixed to the BX51 to image the retinal sections for fluorescence. We then used Adobe Photoshop to layer the images and apply transparency to see the overlap of different fluorophores in a given section area.
###end p 33
###begin title 34
Results
###end title 34
###begin title 35
###xml 16 19 16 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
Levels of VEGF-A164 do not change in the glaucomatous retina
###end title 35
###begin p 36
Average peak IOP was (mean+/-SEM) 40.7+/-1.9 mmHg and 43.1+/-0.8 mmHg for the five-day (n=6) and 10-day (n=6) groups that were used in the western blot (WB) analysis, respectively. Average peak IOP was 43.4+/-0.8 mmHg for the other five-day group used for the immunohistochemistry (IHC) analysis (n=4).
###end p 36
###begin p 37
###xml 87 90 87 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 147 155 147 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 164 167 164 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 270 281 270 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1A,C</xref>
###xml 326 337 326 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1B,C</xref>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 398 401 398 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
In western blots, anti-VEGF antibody detected a 45 kDa band corresponding to the VEGF-A164 dimer in all retinas and in the positive control brain (Figure 1). VEGF-A164 levels remained unchanged between the control and glaucomatous retinas after five days (p=0.341, n=6; Figure 1A,C) and 10 days of elevated IOP (p=0.117, n=6; Figure 1B,C). Using this well characterized antibody [26,27], the VEGF-A164 monomer was not detected in the retina or in the brain.
###end p 37
###begin p 38
###xml 31 34 31 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 74 75 74 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 83 86 83 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 179 180 179 180 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 199 202 199 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 301 302 301 302 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 351 354 351 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 427 430 427 430 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
Western blot analysis of VEGF-A164 expression in the glaucomatous retina. A: VEGF-A164 was detected at 45 kDa in control and glaucomatous retinas after five days of elevated IOP. B: Similarly, VEGF-A164 was observed at 45 kDa in the control and glaucomatous retinas following 10 days of elevated IOP. C: Glaucomatous/control ratio of normalized VEGF-A164 densitometry readings in the retina is demonstrated in the chart. VEGF-A164 was expressed at comparable levels in the control and glaucomatous retinas after five and 10 days of elevated IOP. The positive control was the brain, and the loading control was alpha-tubulin.
###end p 38
###begin p 39
###xml 9 12 9 12 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 133 144 133 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2B,C</xref>
###xml 153 156 153 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 201 210 201 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2E</xref>
###xml 238 247 238 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2H</xref>
###xml 256 259 256 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 337 348 337 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2E,H</xref>
###xml 375 378 375 378 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 451 462 451 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2F,I</xref>
###xml 477 480 477 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
In VEGF-A164 IHC, there was some nonspecific staining in the blood vessels in the RGC layer and INL of the negative control retinas (Figure 2B,C). VEGF-A164 staining did not differ between the normal (Figure 2E) and glaucomatous retinas (Figure 2H). VEGF-A164 expression was localized to the RGC and the cells in the INL of both groups (Figure 2E,H). In the RGC layer, VEGF-A164 staining colocalized with the retinal ganglion cell marker, Fluorogold (Figure 2F,I). Also, VEGF-A164 levels did not differ between the normal and glaucomatous retinas, which are consistent with the WB results.
###end p 39
###begin p 40
###xml 38 41 38 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 113 114 113 114 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 115 116 115 116 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 217 218 217 218 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 219 220 219 220 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 228 231 228 231 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 275 278 275 278 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 315 316 315 316 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 317 318 317 318 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</bold>
###xml 326 329 326 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 421 424 421 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
Immunohistochemical analysis of VEGF-A164 expression in the glaucomatous retina after five days of elevated IOP. A-C: Negative control. Some non-specific staining of blood vessels in the RGC and the INL was observed. D-F: VEGF-A164 staining of the normal retina (n=4). VEGF-A164 was present in the RGC and the INL. G-I: VEGF-A164 staining of the glaucomatous retina (n=4). Staining was detected in the RGC and INL. VEGF-A164 levels did not differ between the normal and glaucomatous retinas.
###end p 40
###begin title 41
###xml 11 15 11 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 50 53 50 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
Anti-VEGF-A165b antibody does not recognize VEGF-A164
###end title 41
###begin p 42
###xml 41 44 41 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 55 59 55 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 156 160 156 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 197 200 197 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 327 330 327 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 359 363 359 363 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 397 401 397 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 439 442 439 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 620 624 620 624 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 640 649 640 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3A</xref>
###xml 760 763 760 763 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 808 817 808 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3B</xref>
###xml 853 856 853 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 962 965 962 965 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 1039 1043 1039 1043 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 1078 1081 1078 1081 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 1097 1101 1097 1101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 317 320 <span type="species:ncbi:10116">rat</span>
###xml 952 955 <span type="species:ncbi:10116">rat</span>
###xml 1122 1125 <span type="species:ncbi:10116">rat</span>
Because it had been predicted that VEGF-A164 and VEGF-A165b are highly homologous in amino acid sequence [18], we first investigated whether the anti-VEGF-A165b antibody would also recognize VEGF-A164. To test this possibility, we immunoblotted different concentrations (25 ng, 100 ng, and 250 ng) of the recombinant rat VEGF-A164 protein with the anti-VEGF-A165b antibody. Whereas the anti-VEGF-A165b antibody did not recognize the VEGF-A164 protein at any concentration, it recognized two bands around 22.4 and 45 kDa in a pair of control and glaucomatous retinas corresponding to the monomer and dimer forms of VEGF-A165b, respectively (Figure 3A). Next, we stripped the membrane and subsequently immunoblotted with the anti-VEGF antibody. A 22.4 kDa VEGF-A164 monomer was detected at all concentrations (Figure 3B), confirming the presence of VEGF-A164 recombinant protein in the same membrane. The dimer form was not observed with the recombinant rat VEGF-A164 protein. The combination of these findings indicated that the anti-VEGF-A165b antibody does not recognize VEGF-A164 and that VEGF-A165b is expressed in the rat retina.
###end p 42
###begin p 43
###xml 11 15 11 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 50 53 50 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</sub>
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>.</sub></italic>
###xml 54 55 54 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 79 83 79 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 129 133 129 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 233 237 233 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 300 303 300 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 365 366 365 366 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 485 488 485 488 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
Anti-VEGF-A165b antibody does not recognize VEGF-A164.A: Incubation with VEGF-A165b antibody. This antibody recognizes the VEGF-A165b monomer (22.5 kDa) and dimer (45 kDa) in control and glaucomatous retinas (first two lanes). VEGF-A165b antibody does not recognize 25 ng, 100 ng, or 250 ng of VEGF-A164 recombinant protein in the same membrane (last three lanes). B: Incubation of the same membrane with the anti-VEGF antibody after stripping. The anti-VEGF antibody recognizes VEGF-A164 recombinant protein at all concentrations.
###end p 43
###begin title 44
###xml 6 10 6 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
VEGF-A165b levels are increased in the glaucomatous retina
###end title 44
###begin p 45
###xml 52 56 52 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 173 177 173 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 193 202 193 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4A</xref>
###xml 219 223 219 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 323 327 323 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 464 475 462 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4A,B</xref>
###xml 566 570 564 568 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 609 613 607 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 683 694 681 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4C,D</xref>
###xml 731 735 729 733 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
Following five days of elevated IOP, the anti-VEGF-A165b antibody detected bands around 22.4 and 45 kDa in all retinas, which represent the monomer and dimer forms of VEGF-A165b, respectively (Figure 4A). Whereas VEGF-A165b dimer levels remained unchanged between the control and glaucomatous retinas (p=0.273, n=6), VEGF-A165b monomer levels were significantly increased in the glaucomatous retinas compared to those in controls (2.33+/-0.44 fold, p=0.014, n=6) (Figure 4A,B). However, following 10 days of elevated IOP, there was no change in levels for the VEGF-A165b dimer (p=0.483, n=6) or for the VEGF-A165b monomer (p=0.864, n=6) between the control and glaucomatous retinas (Figure 4C,D). These results indicate that VEGF-A165b levels increase after five days of elevated IOP and return to baseline levels after 10 days of elevated IOP.
###end p 45
###begin p 46
###xml 31 35 31 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 75 76 75 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 84 88 84 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 151 155 151 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 222 223 222 223 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 272 276 272 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 383 387 383 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 470 471 470 471 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 479 483 479 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 536 540 536 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 621 622 621 622 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 671 675 671 675 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 778 782 778 782 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 932 935 932 935 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
Western blot analysis of VEGF-A165b expression in the glaucomatous retina. A: VEGF-A165b expression following five days of elevated IOP. Retinal VEGF-A165b monomer and dimer were detected at 22.5 and 45 kDa, respectively. B: Glaucomatous/control ratio of normalized VEGF-A165b densitometry readings in the retina following five days of elevated IOP. Expression of the 22.5 kDa VEGF-A165b was increased significantly in the glaucomatous retinas compared to the controls. C: VEGF-A165b expression following 10 days of elevated IOP. VEGF-A165b monomer and dimer were observed at 22.5 and 45 kDa in the retina, respectively. D: Glaucomatous/control ratio of normalized VEGF-A165b densitometry readings in the retina following 10 days of elevated IOP. Both 22.5 kDa and 45 kDa VEGF-A165b were expressed at comparable levels in the control and glaucomatous retinas. The positive control was the brain while the negative control was VEGF-A164 recombinant protein. The loading control was alpha-tubulin.
###end p 46
###begin p 47
###xml 48 52 48 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 82 85 82 85 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 93 97 93 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 163 174 163 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5E,H</xref>
###xml 248 263 248 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5F,I,O,R</xref>
###xml 350 361 350 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5B,K</xref>
###xml 442 446 442 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 520 531 520 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5H,Q</xref>
###xml 539 550 539 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5E,N</xref>
IHC demonstrated that the distribution of VEGF-A165b was similar to that of VEGF-A164. VEGF-A165b staining was observed in the RGC and in the inner nuclear layer (Figure 5E,H). In the RGC layer, staining overlapped with the RGC marker, Fluorogold (Figure 5F,I,O,R). No staining was observed in the negative control with the primary antibody omitted (Figure 5B,K). Consistent with our WB results, IHC analysis showed increased levels of VEGF-A165b immunoreactivity in the glaucomatous retinas compared to normal retinas (Figure 5H,Q verses Figure 5E,N, respectively).
###end p 47
###begin p 48
###xml 38 42 38 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 114 115 114 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 116 117 116 117 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 191 192 191 192 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 193 194 193 194 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 202 206 202 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 250 254 250 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 291 292 291 292 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 293 294 293 294 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</bold>
###xml 302 306 302 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 356 360 356 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 437 438 437 438 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">J</bold>
###xml 439 440 439 440 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</bold>
###xml 513 514 513 514 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</bold>
###xml 515 516 515 516 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</bold>
###xml 524 528 524 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 629 630 629 630 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</bold>
###xml 631 632 631 632 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</bold>
###xml 640 644 640 644 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 709 713 709 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
Immunohistochemical analysis of VEGF-A165b expression in the glaucomatous retina after five days of elevated IOP. A-C: Negative control. Non-specific staining was not detected in the retina. D-F: VEGF-A165b staining of the normal retina (n=4). VEGF-A165b was present in the RGC and the INL. G-I: VEGF-A165b staining of the glaucomatous retina (n=4). VEGF-A165b staining was stronger in the RGC and the INL compared to the normal retina. J-L: Negative control. No non-specific staining was observed in the retina. M-O: VEGF-A165b staining of the RGC in the normal retina. Staining was colocalized with the RGC marker, Fluorogold. P-R: VEGF-A165b staining of the RGC in the glaucomatous retina. Levels of VEGF-A165b in the Fluorogold-labeled RGC (white arrow) were increased in the retinas with elevated IOP.
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 41 45 41 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 103 107 103 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 226 230 226 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 282 285 282 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 334 337 334 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 420 424 420 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 451 455 451 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 64 67 <span type="species:ncbi:10116">rat</span>
We demonstrate in this report that VEGF-A165b is present in the rat. In particular, we show that VEGF-A165b is present in the retina and localized primarily to the RGC layer and the inner nuclear layer. Our findings for VEGF-A165b show a distribution similar to that seen for VEGF-A164 in this report and previous reports about VEGF-A164 by others [28,29]. Using back labeling techniques, we find that RGC express VEGF-A165b. Our data show that VEGF-A165b levels are increased early in the cause of experimental glaucoma but return to baseline at a later time point. IHC results show that this increase is primarily due to increased expression in the RGC layer and in the INL.
###end p 50
###begin p 51
###xml 69 72 69 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 253 256 253 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 149 152 <span type="species:ncbi:10116">rat</span>
Our results demonstrate that the levels for the pro-angiogenic VEGF-A164 do not change in the glaucomatous retina compared to control retinas in the rat after five days or 10 days of elevated IOP. Consistent with previous studies, we observe that VEGF-A164 is expressed in the RGC and INL of the retina [28,29].
###end p 51
###begin p 52
###xml 6 9 6 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 97 100 97 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 111 115 111 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 199 202 199 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 213 217 213 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 351 354 351 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 380 384 380 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 480 484 480 484 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 1105 1107 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 1159 1163 1159 1163 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 1204 1206 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 1207 1209 1207 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 317 323 <span type="species:ncbi:9606">humans</span>
###xml 520 525 <span type="species:ncbi:10090">mouse</span>
###xml 951 956 <span type="species:ncbi:9606">human</span>
###xml 957 965 <span type="species:ncbi:9606">patients</span>
VEGF-A165 is the most abundantly expressed pro-angiogenic isoform in the retina [17]. Both VEGF-A165 and VEGF-A165b mRNA are produced from the VEGF-A pre-mRNA via alternative splicing [15,18]. VEGF-A165 and VEGF-A165b share a 96.4% homology and differ only in the last six amino acids in their amino acid sequence in humans [18]. However, while VEGF-A165 is pro-angiogenic, VEGF-A165b has an inhibitory effect on angiogenesis both in vitro and in vivo [18,19]. For example, VEGF-A165b inhibits neovascularization in the mouse retina following oxygen-induced retinopathy [21]. More recently, other inhibitory splice variants of VEGF-A have also been identified [19,20]. It has been suggested that the relative levels of the pro-angiogenic and anti-angiogenic VEGF-A isoforms determine whether angiogenesis will be stimulated or inhibited in a tissue [20]. For instance, the expression of the pro-angiogenic VEGF-A isoforms increases in the vitreous of human patients with diabetic retinopathy whereas the expression of the anti-angiogenic VEGF-A isoforms remains unchanged compared to the normal vitreous [20]. Among the anti-angiogenic VEGF-A isoforms, VEGF-A165b is observed to be the dominant isoform [15,18].
###end p 52
###begin p 53
###xml 70 74 70 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 337 343 337 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF-A</italic>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 951 953 951 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 954 956 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 957 959 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 1039 1041 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 1206 1208 1206 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 1209 1211 1209 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 1431 1433 1431 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
What molecular mechanism is responsible for the upregulation of VEGF-A165b mRNA in the glaucomatous retina? Although the precise answer remains unknown, proposed mechanisms include differential promoter selection, alternate regulation of mRNA stability, and regulation of alternative splicing [15,30-33]. In alternative splicing, as the VEGF-A gene is being transcribed, the emerging pre-mRNA is instantaneously processed by several RNA-binding proteins and splice factors [15]. These proteins bind to the auxiliary sequences on the pre-mRNA and determine which exons will be spliced [34]. It is thought that several signal transduction pathways, which are activated in response to changes in the environment (e.g., receptor-mediated pathways, neuronal activity, cellular stress-like hypoxia) affect alternative splicing by altering the relative levels of RNA-binding proteins and splice factors or the localization of splice factors within the cell [15,35,36]. More recently, microRNAs have also been shown to alter alternative splicing [37]. For example, in muscle and neuronal development, microRNAs lead to the inclusion of alternative exons by suppressing a repressor protein of alternative splicing [38,39]. In addition, transcriptional events may also affect the regulation of alternative splicing. For instance, the speed of RNA polymerase II can influence the choice of splice sites and recruitment of regulatory factors [40].
###end p 53
###begin p 54
###xml 88 92 88 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 126 129 126 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 237 241 237 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165b</sub>
###xml 286 289 286 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
In conclusion, we report an increase in the retinal levels of the anti-angiogenic VEGF-A165b but not the pro-angiogenic VEGF-A164 in our experimental glaucoma model. The combination of these findings suggests that the elevation of VEGF-A165b levels and/or the unchanged levels of VEGF-A164 contribute to the lack of neovascularization in the retina in glaucoma.
###end p 54
###begin title 55
Acknowledgments
###end title 55
###begin p 56
###xml 95 100 <span type="species:ncbi:9689">Lions</span>
This work was financially supported by R01-EY13399 (C.L.G.), T32-EY07145 (C.E.), Massachusetts Lions Grant (C.L.G.), and MEEI Vision-Core Grant EY014104.
###end p 56
###begin title 57
References
###end title 57
###begin article-title 58
###xml 58 66 <span type="species:ncbi:9606">Patients</span>
Retinal Blood Flow Response to Posture Change in Glaucoma Patients Compared with Healthy Subjects.
###end article-title 58
###begin article-title 59
Detection of disturbed autoregulation of the peripapillary choroid in primary open angle glaucoma.
###end article-title 59
###begin article-title 60
Choroidal vascular reaction to hand-grip stress in subjects with vasospasm and its relevance in glaucoma.
###end article-title 60
###begin article-title 61
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Ocular blood flow and systemic blood pressure in patients with primary open-angle glaucoma and ocular hypertension.
###end article-title 61
###begin article-title 62
Diurnal variation in microcirculation of ocular fundus and visual field change in normal-tension glaucoma.
###end article-title 62
###begin article-title 63
###xml 9 17 <span type="species:ncbi:9606">patients</span>
Glaucoma patients demonstrate faulty autoregulation of ocular blood flow during posture change.
###end article-title 63
###begin article-title 64
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Compromised autoregulatory control of ocular hemodynamics in glaucoma patients after postural change.
###end article-title 64
###begin article-title 65
Retinal autoregulation in open-angle glaucoma.
###end article-title 65
###begin article-title 66
The impact of ocular blood flow in glaucoma.
###end article-title 66
###begin article-title 67
Optic nerve blood flow in glaucoma.
###end article-title 67
###begin article-title 68
HIF-1: mediator of physiological and pathophysiological responses to hypoxia.
###end article-title 68
###begin article-title 69
Biology of vascular endothelial growth factors.
###end article-title 69
###begin article-title 70
VEGF is major stimulator in model of choroidal neovascularization.
###end article-title 70
###begin article-title 71
Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.
###end article-title 71
###begin article-title 72
Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm.
###end article-title 72
###begin article-title 73
The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease.
###end article-title 73
###begin article-title 74
###xml 56 61 <span type="species:ncbi:9606">human</span>
Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy.
###end article-title 74
###begin article-title 75
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.
###end article-title 75
###begin article-title 76
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.
###end article-title 76
###begin article-title 77
Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.
###end article-title 77
###begin article-title 78
###xml 98 102 <span type="species:ncbi:10090">mice</span>
VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice.
###end article-title 78
###begin article-title 79
Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von Willebrand factor in glaucoma.
###end article-title 79
###begin article-title 80
Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes.
###end article-title 80
###begin article-title 81
###xml 2 5 <span type="species:ncbi:10116">rat</span>
A rat model of chronic pressure-induced optic nerve damage.
###end article-title 81
###begin article-title 82
###xml 27 30 <span type="species:ncbi:10116">rat</span>
Noninvasive measurement of rat intraocular pressure with the Tono-Pen.
###end article-title 82
###begin article-title 83
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.
###end article-title 83
###begin article-title 84
Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization.
###end article-title 84
###begin article-title 85
Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes.
###end article-title 85
###begin article-title 86
Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression.
###end article-title 86
###begin article-title 87
The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term.
###end article-title 87
###begin article-title 88
New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation.
###end article-title 88
###begin article-title 89
###xml 18 23 <span type="species:ncbi:9606">human</span>
Sequencing of the human vascular endothelial growth factor (VEGF) 3' untranslated region (UTR): conservation of five hypoxia-inducible RNA-protein binding sites.
###end article-title 89
###begin article-title 90
###xml 15 20 <span type="species:ncbi:9606">human</span>
Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein.
###end article-title 90
###begin article-title 91
Understanding alternative splicing: towards a cellular code.
###end article-title 91
###begin article-title 92
###xml 96 101 <span type="species:ncbi:9606">human</span>
Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome.
###end article-title 92
###begin article-title 93
Alternative splicing: a new drug target of the post-genome era.
###end article-title 93
###begin article-title 94
Multilevel regulation of gene expression by microRNAs.
###end article-title 94
###begin article-title 95
MicroRNAs regulate the expression of the alternative splicing factor nPTB during muscle development.
###end article-title 95
###begin article-title 96
The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing.
###end article-title 96
###begin article-title 97
Chromatin, transcript elongation and alternative splicing.
###end article-title 97

